WEBULL
WebtradeDownload

Immunome (IMNM) Stock Dropped, What Is Behind The Latest Attention?

Simply Wall St · 1d ago

FDA clearance for IM-1340 puts Immunome in focus

Immunome (IMNM) has come into the spotlight after the FDA cleared its IND application for IM-1340, a potential first in class antibody drug conjugate targeting multiple advanced solid tumor types.

That clearance dropped into a weak tape for Immunome, with the 1 day share price return down 8.2% to US$17.58 and the 30 day share price return down 28.7%, even though the 1 year total shareholder return is up 24.7% and the 3 year total shareholder return has roughly doubled. This suggests long term holders have still been rewarded while short term momentum has faded as investors reassess how much near term risk to price into this broader oncology platform.

See how Immunome compares to other oncology-focused plays by reviewing a curated set of 20 high quality undiscovered gems that the market may not be fully pricing in yet.

Immunome now trades at a steep discount to both intrinsic value estimates and analyst targets after the pullback. This could represent a margin of safety, or it could be a warning sign that the market perceives meaningful risk in the company’s profile.

Most Popular Narrative: 52% Undervalued

On the most followed narrative, Immunome’s fair value sits at $36.31 against a last close of $17.58. This frames the recent pullback as a deep discount that only pays off if the long pipeline story holds together.

The move from a single lead asset to a broader Immunome oncology platform, with IM-1021, IM-1617 and IM-3050 already in Phase 1 and two additional solid tumor ADC INDs planned for 2026, increases the number of shots on goal that could support multi-asset revenue streams and help spread fixed costs over a larger base, which may benefit margins over time.

See why 1 investors see Immunome as 52% undervalued.

Result: Fair Value of $36.31 (UNDERVALUED)

Still, two pressure points could quickly shift the Immunome story: any setback on varegacestat’s desmoid tumor review, or slower than expected uptake if it is approved.

Find out about the key risks to this Immunome narrative.

Next Steps

Uncertain about how the mixed mood around Immunome should shape your next move? Consider your options while sentiment remains divided and weigh the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Immunome?

If you want a wider watchlist before making your next move, let the Simply Wall Street Screener surface high conviction ideas tailored to different risk and income preferences.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.